MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Royalty Pharma plc EBITDA per Share 2011-2026 | RPRX
Annual EBITDA per Share Royalty Pharma plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.64 | - | - | 0.71 | 3.5 | 4.31 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.31 | 0.71 | 3.04 |
Quarterly EBITDA per Share Royalty Pharma plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | 0.44 | 0.87 | 0.52 | - | 0.72 | 1.83 | 0.6 | - | 1.4 | 1.17 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.83 | 0.44 | 0.944 |
EBITDA per Share of other stocks in the Biotechnology industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.2 | - | 2.43 % | $ 254 M |  Germany |
 |
Altimmune
ALT
|
-1.07 | $ 3.47 | 3.89 % | $ 306 M |  USA |
 |
I-Mab
IMAB
|
0.08 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.75 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-2.24 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-0.23 | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-8.25 | $ 219.83 | -0.92 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
-0.09 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.22 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
-5.25 | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-0.08 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-188 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-6.41 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-3.63 | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
-1.38 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
-2.69 | - | - | - |  Russia |
 |
Grifols, S.A.
GRFS
|
0.87 | $ 7.69 | 1.39 % | $ 6.83 B |  Spain |
 |
Avenue Therapeutics
ATXI
|
-8.71 | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-6.85 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-1.56 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-5.96 | - | -9.65 % | $ 45.9 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-1.42 | $ 0.6 | -2.83 % | $ 6.87 M |  Israel |
 |
Ayala Pharmaceuticals
AYLA
|
-2.42 | - | - | $ 7.46 M | Israel |
 |
Cullinan Management
CGEM
|
-4.01 | $ 13.01 | 2.12 % | $ 784 M | USA |
 |
Atreca
BCEL
|
0.14 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
0.38 | - | -4.8 % | $ 255 M | USA |
 |
Heron Therapeutics
HRTX
|
-0.06 | $ 0.8 | 2.29 % | $ 133 M | USA |
 |
BeiGene, Ltd.
BGNE
|
0.42 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
-1.56 | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
-2.24 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-1.82 K | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-2.34 | - | -74.18 % | $ 955 K | USA |
 |
Incyte Corporation
INCY
|
8.24 | $ 91.13 | 0.38 % | $ 17.8 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
-1.42 | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-1.88 | - | -7.23 % | $ 13 M | USA |
 |
Inovio Pharmaceuticals
INO
|
-6.37 | $ 1.6 | 0.95 % | $ 35.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-6.7 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-2.22 | - | - | $ 867 M | Germany |
 |
Denali Therapeutics
DNLI
|
-2.92 | $ 21.15 | 4.86 % | $ 3.48 B | USA |
 |
Akero Therapeutics
AKRO
|
-4.25 | - | - | $ 3.67 B | USA |
 |
Inventiva S.A.
IVA
|
-1.33 | $ 6.07 | 5.02 % | $ 138 M | France |
 |
Arbutus Biopharma Corporation
ABUS
|
-0.46 | $ 4.3 | 1.3 % | $ 714 M | Canada |
 |
Akouos
AKUS
|
-2.45 | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
-1.85 | - | 1.93 % | $ 17.4 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-0.54 | - | -5.98 % | $ 34.1 M | USA |
 |
Decibel Therapeutics
DBTX
|
-2.5 | - | - | $ 123 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-2.46 | - | - | $ 2.18 B | USA |
 |
Cardiff Oncology
CRDF
|
-0.73 | $ 1.8 | 0.08 % | $ 120 M | USA |